BIOAGE LABS, INC. (BIOA) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $757.16M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-478.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $734.72M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $73.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $605.19M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $278.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $584.66M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $275.00K.
BIOAGE LABS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $0.00 | $757.16M | $-478.00K | $-381.77M | $374.91M | 3 month · $4.27M |
| 2026-03-31 | $0.00 | $0.00 | $734.72M | $73.00K | $-355.67M | $379.12M | 3 month · $4.26M |
| 2025-12-31 | $0.00 | $0.00 | $605.19M | $278.00K | $-333.42M | $272.05M | 12 month · $11.69M |
| 2025-09-30 | $0.00 | $0.00 | $584.66M | $275.00K | $-307.47M | $277.46M | 3 month · $2.79M |
| 2025-06-30 | $0.00 | $0.00 | $581.87M | $212.00K | $-287.30M | $294.78M | 3 month · $3.23M |
| 2025-03-31 | (m) | (m) | $578.64M | $264.00K | $-265.74M | $313.17M | 3 month · $2.95M |
| 2024-12-31 | $0.00 | $0.00 | $575.69M | $245.00K | $-252.81M | $323.13M | 12 month · $6.98M |
| 2024-09-30 | (m) | (m) | $545.32M | $109.00K | $-231.68M | $313.75M | 3 month · $1.85M |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | $-197.13M | 3 month · $1.56M |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | $-185.51M | 3 month · $852.00K |
| 2023-12-31 | (m) | $0.00 | $8.14M | $164.00K | $-181.70M | $-173.40M | 12 month · $3.02M |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | $-153.14M | 3 month · $757.00K |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | $-139.31M | 3 month · $758.00K |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | $-122.92M | 3 month · $734.00K |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | $-112.56M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |